Trial reportThe Journal of allergy and clinical immunology2015
Sublingual immunotherapy for peanut allergy: Long-term follow-up of a randomized multicenter trial.
Trial report in The Journal of allergy and clinical immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00580606 (Sublingual Immunotherapy for Peanut Allergy), which is not on this map. Cited by 64 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Sublingual Immunotherapy for Peanut Allergy: A Randomized, Double-Blind, Placebo-Controlled, Phase I/II Pilot Study With a Whole Peanut Extract
Who cites it
64 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Racial and Ethnic Representation in Food Allergen Immunotherapy Trial Participants: A Systematic Review.JAMA network open · 2024Pooled it
- Desensitization and remission after peanut sublingual immunotherapy in 1- to 4-year-old peanut-allergic children: A randomized, placebo-controlled trial.The Journal of allergy and clinical immunology · 2024Trial
- Open-label study of the efficacy, safety, and durability of peanut sublingual immunotherapy in peanut-allergic children.The Journal of allergy and clinical immunology · 2023Trial
- Epicutaneous immunotherapy for treatment of peanut allergy: Follow-up from the Consortium for Food Allergy Research.The Journal of allergy and clinical immunology · 2021Trial
- Long-term sublingual immunotherapy for peanut allergy in children: Clinical and immunologic evidence of desensitization.The Journal of allergy and clinical immunology · 2019Trial
- Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults.The Journal of allergy and clinical immunology · 2017Trial
- Safety, clinical, and immunologic efficacy of a Chinese herbal medicine (Food Allergy Herbal Formula-2) for food allergy.The Journal of allergy and clinical immunology · 2015Trial
- The Etiology of IgE-Mediated Food Allergy: Potential Therapeutics and Challenges.International journal of molecular sciences · 2025Review
- A review of sublingual immunotherapy for treatment of peanut allergy.Journal of food allergy · 2024Article
- Sublingual immunotherapy for allergy to shrimp: the nine-year clinical experience of a Midwest Allergy-Immunology practice.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2024Article
- Food Allergen Immunotherapy in the Treatment of Patients with IgE-Mediated Food Allergy.Medicina (Kaunas, Lithuania) · 2024Review
- WALKING BACKWARDS: REFLECTING ON THE VALUE OF MENTORS.Transactions of the American Clinical and Climatological Association · 2024Article
- Combined LTP Sublingual and Oral Immunotherapy in LTP Syndrome: Efficacy and Safety.Journal of clinical medicine · 2023Article
- Update on clinical research for food allergy treatment.Frontiers in allergy · 2023Review
- Review
- Treatment Approaches to Food Allergy.Handbook of experimental pharmacology · 2022Review
- Oral Immunotherapy for Children with Cow's Milk Allergy.Pathogens (Basel, Switzerland) · 2021Review
- Basophil activation test in food allergy: is it ready for real-time?Current opinion in allergy and clinical immunology · 2021Review
- Regulatory Requirements for the Quality of Allergen Products for Allergen Immunotherapy of Food Allergy.Current allergy and asthma reports · 2021Review
- Oral Mucosa as a Potential Site for Diagnosis and Treatment of Allergic and Autoimmune Diseases.Foods (Basel, Switzerland) · 2021Review
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundWe previously reported the initial results of the first multicenter, randomized, double-blind, placebo-controlled clinical trial of peanut sublingual immunotherapy (SLIT), observing a favorable safety profile associated with modest clinical and immunologic effects in the first year.
objectiveWe sought to provide long-term (3-year) clinical and immunologic outcomes for our peanut SLIT trial. Key end points were (1) percentage of responders at 2 years (ie, could consume 5 g of peanut powder or a 10-fold increase from baseline), (2) percentage reaching desensitization at 3 years, (3) percentage attaining sustained unresponsiveness after 3 years, (4) immunologic end points, and (5) assessment of safety parameters.
methodsResponse to treatment was evaluated in 40 subjects aged 12 to 40 years by performing a 10-g peanut powder oral food challenge after 2 and 3 years of daily peanut SLIT therapy. At 3 years, SLIT was discontinued for 8 weeks, followed by another 10-g oral food challenge and an open feeding of peanut butter to assess sustained unresponsiveness.
resultsApproximately 98% of the 18,165 doses were tolerated without adverse reactions beyond the oropharynx, with no severe symptoms or uses of epinephrine. A high rate (>50%) discontinued therapy. By study's end, 4 (10.8%) of 37 SLIT-treated participants were fully desensitized to 10 g of peanut powder, and all 4 achieved sustained unresponsiveness. Responders at 2 years showed a significant decrease in peanut-specific basophil activation and skin prick test titration compared with nonresponders.
conclusionsPeanut SLIT induced a modest level of desensitization, decreased immunologic activity over 3 years in responders, and had an excellent long-term safety profile. However, most patients discontinued therapy by the end of year 3, and only 10.8% of subjects achieved sustained unresponsiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.